Understanding the Key Differences Between These Treatments
Wegovy Doses Compared to Mounjaro: UK Stock Availability
When comparing Wegovy doses to Mounjaro, UK availability has historically been a major concern for patients. EverydayMeds maintains comprehensive stock of both treatments, ensuring you won't face delays regardless of which your prescriber recommends. Our Wegovy inventory includes all five doses from 0.25mg starter through to 2.4mg maintenance, whilst our Mounjaro stock covers the complete range from 2.5mg to 15mg. This reliable supply chain, backed by our GPhC #9012878 registration, means you can start treatment immediately rather than joining waitlists.
The practical advantage extends beyond simple availability – having both treatments in stock allows your prescriber genuine choice based on your clinical needs rather than supply constraints. Whether you require Wegovy's proven GLP-1 pathway or Mounjaro's innovative dual-hormone approach, EverydayMeds ensures your prescribed treatment arrives via next-day cold-chain delivery. This eliminates the treatment interruptions that have historically affected UK patients, particularly during Wegovy's supply challenges in 2022-2023.
Pricing Structure: Wegovy vs Mounjaro Dose Costs
Understanding Wegovy doses compared to Mounjaro involves examining the different pricing structures for each treatment pathway. Wegovy follows a graduated pricing model reflecting dose escalation: £79.99 for the 0.25mg starter (after FIRST40 discount for new customers), rising to £209.99 for the 2.4mg maintenance dose. Our bundle options like the Intro Duo (0.25mg & 0.5mg) at £169.99 provide convenient multi-month supplies. Mounjaro pricing differs due to its distinct dosing schedule and mechanism, with costs varying across the 2.5mg to 15mg range.
Both treatments qualify for our discount codes – FIRST40 for new customers and DOSE25 for returning patients – applied automatically at checkout to reach these final prices. The investment reflects each treatment's research and development costs, with Wegovy backed by the extensive STEP trial programme and Mounjaro by the SURMOUNT studies. Remember these are prescription-only medicines requiring clinical assessment, so your final treatment choice should prioritise clinical suitability over cost considerations alone.
Clinical Evidence: STEP vs SURMOUNT Trial Data
The clinical foundation for Wegovy doses compared to Mounjaro stems from separate trial programmes with different primary endpoints. Wegovy's efficacy was established through the STEP trials, with STEP 1 showing participants achieved approximately 15% average weight loss at 68 weeks when taking the medication alongside diet and exercise (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained results with approximately 15.2% weight reduction maintained at two years, whilst SELECT trial revealed a 20% reduction in major cardiovascular events.
Mounjaro's evidence base derives from the SURMOUNT programme, though direct comparison between these studies isn't appropriate due to different trial designs, participant populations, and measurement protocols. Both treatments demonstrated efficacy when combined with reduced-calorie diet and increased physical activity, supporting their respective MHRA approvals for weight management. Your prescriber will evaluate which evidence base aligns better with your individual health profile and treatment goals.
How Wegovy's GLP-1 Mechanism Differs from Mounjaro's Dual Action
Wegovy operates as a selective GLP-1 receptor agonist, mimicking the natural incretin hormone that signals satiety to your brain's appetite centres. This mechanism reduces hunger between meals and promotes feeling full with smaller portions, effectively supporting portion control when combined with dietary changes. The once-weekly injection via FlexTouch pen maintains consistent GLP-1 activity throughout the week, helping regulate both appetite and gastric emptying. Unlike single-pathway approaches, this targeted GLP-1 activation has undergone extensive study specifically for weight management applications. The gradual dose escalation from 0.25mg to 2.4mg allows your body to adapt whilst minimising potential gastrointestinal side effects common to GLP-1 treatments.
Streamlined Ordering Process for Both Treatments
Accessing Wegovy doses compared to Mounjaro through EverydayMeds follows our standardised clinical pathway regardless of which treatment your prescriber selects. The process begins with a comprehensive 3-minute online assessment covering your medical history, current medications, weight management goals, and any contraindications to either treatment. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), ensuring thorough evaluation before approving your prescription-only medicine. Once approved, your treatment ships via temperature-controlled next-day delivery, maintaining the cold-chain integrity essential for both injectable medications. This streamlined approach eliminates traditional barriers to accessing weight management treatments whilst maintaining full clinical oversight and MHRA compliance.
Storage and Practical Considerations
One significant practical difference when comparing Wegovy doses to Mounjaro lies in storage flexibility, particularly important for UK patients who travel or lack reliable refrigeration. Wegovy pens remain stable for up to 6 weeks at room temperature below 30°C once removed from refrigerated storage, compared to Mounjaro's 21-day room temperature limit. Both require initial storage at 2-8°C, but Wegovy's extended room temperature stability provides greater flexibility for holidays, business travel, or temporary accommodation changes. The FlexTouch pen design used for Wegovy delivers precise doses with an easy-to-read counter, whilst both treatments follow structured dose escalation schedules to optimise tolerance. Your prescriber will provide specific guidance on transitioning between doses, whether following Wegovy's 4-week intervals or Mounjaro's distinct titration schedule.
UK Supply Chain Reliability: Wegovy and Mounjaro Availability
EverydayMeds' approach to Wegovy doses compared to Mounjaro centres on maintaining robust UK inventory levels that prevent treatment disruptions. Our direct relationships with Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro) ensure consistent supply flows, backed by sophisticated demand forecasting that accounts for seasonal variations and prescribing trends. This infrastructure proved crucial during Wegovy's 2022-2023 supply constraints, when many patients faced treatment delays or interruptions that could compromise their weight management progress.
The dual-stock approach means your treatment continuity remains protected regardless of manufacturer-level supply fluctuations affecting either medication. Our GPhC #9012878 registration requires maintaining appropriate stock levels whilst ensuring proper cold-chain storage throughout our facility. This professional standard means your prescribed dose ships immediately rather than being backordered, maintaining the consistent weekly dosing schedule essential for both treatments' efficacy.
Making Your Treatment Decision with Confidence
Both Wegovy and Mounjaro represent significant advances in weight management treatment, each offering distinct mechanisms and dosing approaches suited to different patient profiles. EverydayMeds stocks both treatments comprehensively, allowing your prescriber to recommend based purely on clinical appropriateness rather than availability constraints. Whether you proceed with Wegovy's proven GLP-1 pathway starting at £79.99, or explore Mounjaro's innovative dual-hormone approach, our clinical team ensures proper assessment and ongoing support throughout your treatment journey. New customers can apply discount code FIRST40 at checkout, while returning patients use DOSE25 to access our competitive pricing across both treatment options. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment today, knowing both leading weight management treatments await your prescriber's decision with immediate UK availability and next-day delivery.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
